[go: up one dir, main page]

AR081409A1 - PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV) - Google Patents

PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV)

Info

Publication number
AR081409A1
AR081409A1 ARP110101750A ARP110101750A AR081409A1 AR 081409 A1 AR081409 A1 AR 081409A1 AR P110101750 A ARP110101750 A AR P110101750A AR P110101750 A ARP110101750 A AR P110101750A AR 081409 A1 AR081409 A1 AR 081409A1
Authority
AR
Argentina
Prior art keywords
virus
rabia
parapoxvirus
recombining
dna derived
Prior art date
Application number
ARP110101750A
Other languages
English (en)
Inventor
Olivier Michel Martinon
Nanda Kumar Damavarapu Reddy
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR081409A1 publication Critical patent/AR081409A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Parapoxvirus recombinantes que comprenden ADN heterologo en el genoma, derivado de un virus de la rabia, la preparacion de dichos constructos y su uso en composiciones inmunogénicas y vacunas, También al uso de parapoxvirus recombinantes para diagnostico de animales infectados. Reivindicacinn 17: Un método para inducir una respuesta inmune contra el virus de la rabia en un animal, caracterizado porque comprende administrarle a dicho animal una cantidad inmunologicamente eficaz de una composicion inmunogénica de acuerdo con la reivindicacion 15. Reivindicacinn 18: El método de acuerdo con la reivindicacion 17, caracterizado porque la respuesta inmune es la induccion de anticuerpos de suero de antiproteína G.
ARP110101750A 2010-05-21 2011-05-20 PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV) AR081409A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34698810P 2010-05-21 2010-05-21
US41428710P 2010-11-16 2010-11-16

Publications (1)

Publication Number Publication Date
AR081409A1 true AR081409A1 (es) 2012-08-29

Family

ID=44972661

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101750A AR081409A1 (es) 2010-05-21 2011-05-20 PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV)

Country Status (18)

Country Link
US (1) US20110287051A1 (es)
EP (1) EP2571521A1 (es)
JP (1) JP5890399B2 (es)
KR (2) KR20150015551A (es)
CN (1) CN103260644A (es)
AR (1) AR081409A1 (es)
AU (1) AU2011254315B2 (es)
BR (1) BR112012029633A8 (es)
CA (1) CA2798055C (es)
CL (1) CL2012003219A1 (es)
CO (1) CO6670515A2 (es)
MX (1) MX338052B (es)
NZ (1) NZ603431A (es)
PH (1) PH12012502301A1 (es)
RU (1) RU2545694C2 (es)
UY (1) UY33400A (es)
WO (1) WO2011145013A1 (es)
ZA (1) ZA201208264B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102014116334A1 (de) * 2014-11-10 2016-05-12 Eberhard Karls Universität Tübingen Medizinische Fakultät Herstellung von rekombinanten Expressionsvektoren
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
BR112018069371A2 (pt) * 2016-03-21 2019-01-22 South Dakota Board Of Regents construção de ácido nucleico, vetor, vacina ou composição imunogênica, método de entrega de uma vacina, método de produção de uma construção de ácido nucleico e método para conferir imunidade contra um antígeno
CN111944769B (zh) * 2020-08-10 2022-06-28 塔里木大学 一种狂犬病毒g蛋白-羊痘病毒重组疫苗的构建方法
CA3192853A1 (en) * 2020-08-13 2022-02-17 Suzhou Prajna Biotech Co., Ltd. Mutant orf viruses and uses thereof
CN117298263B (zh) * 2023-09-27 2025-01-28 成都迈科康生物科技有限公司 一种重组狂犬病疫苗及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
EP0237686A1 (en) * 1986-03-18 1987-09-23 Institut Pasteur DNA sequences derived from the rabies virus genome
CN1217027A (zh) * 1996-02-28 1999-05-19 拜尔公司 含外源dna的副痘病毒,其制备及其在疫苗中的应用
US6844000B2 (en) * 2001-12-07 2005-01-18 Bayer Pharmaceuticals Corporation Use of Parapox B2L protein to treat cancer and modify immune responses
DE60205388T2 (de) 2001-12-10 2006-03-30 Bavarian Nordic A/S Poxvirus-enthaltende zusammensetzungen und verfahren zu ihrer herstellung
AU2008363648B9 (en) * 2008-10-31 2013-08-22 Tremrx, Inc. Vaccination with poxvirus vectors via mechanical epidermal disruption

Also Published As

Publication number Publication date
NZ603431A (en) 2014-06-27
BR112012029633A2 (pt) 2016-09-20
MX2012013451A (es) 2013-01-22
US20110287051A1 (en) 2011-11-24
CL2012003219A1 (es) 2013-04-05
CA2798055C (en) 2015-11-24
JP5890399B2 (ja) 2016-03-22
RU2012149036A (ru) 2014-06-27
KR20130008645A (ko) 2013-01-22
JP2013535953A (ja) 2013-09-19
BR112012029633A8 (pt) 2017-12-05
RU2545694C2 (ru) 2015-04-10
KR20150015551A (ko) 2015-02-10
EP2571521A1 (en) 2013-03-27
WO2011145013A1 (en) 2011-11-24
CA2798055A1 (en) 2011-11-24
AU2011254315A1 (en) 2013-01-10
ZA201208264B (en) 2014-01-29
MX338052B (es) 2016-03-31
CO6670515A2 (es) 2013-05-15
CN103260644A (zh) 2013-08-21
PH12012502301A1 (en) 2013-02-04
AU2011254315B2 (en) 2015-05-14
UY33400A (es) 2011-12-30

Similar Documents

Publication Publication Date Title
Herbert et al. Recombinant adenovirus expressing the haemagglutinin of peste des petits ruminants virus (PPRV) protects goats against challenge with pathogenic virus; a DIVA vaccine for PPR
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
AR081409A1 (es) PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV)
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
EA201590597A1 (ru) Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
MX2013004303A (es) Vacuna vectorizada por el herpesvirus de los pavos contra la influenza aviar en aves de corral.
AR071910A1 (es) Vacuna combinada para el papiloma humano y el sarampion. vector. huesped.
AR061894A1 (es) Vacunas para malaria
EP2568289A3 (en) Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
MX383416B (es) Nueva vacuna contra la influenza porcina.
PH12013501116A1 (en) Raccoon poxvirus expressing rabies glycoproteins
CO7461133A2 (es) Parvovirus 5a porcino, métodos de uso y vacuna
AR082281A1 (es) Vectores de parapoxvirus
CU20120057A7 (es) Composición vacunal contra el virus del dengue, kit y plásmido
EA201500140A1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
EA033242B1 (ru) Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением
AR066823A1 (es) Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp
EA201401044A1 (ru) Модифицированный вирус болезни марека и вакцины на его основе
NZ733235A (en) Foot-and-mouth disease vaccine
AR105134A1 (es) Vacunas contra la influenza con coincidencia antigénica
NZ733235B2 (en) Foot-and-mouth disease vaccine

Legal Events

Date Code Title Description
FB Suspension of granting procedure